ClinicalTrials.gg
CompletedNCT04880993Updated May 11, 2021

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

A Phase 1 interventional study of Dapagliflozin 10 mg tablets and Farxiga® 10 mg tablets in Healthy Subjects, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2020, registered Apr 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the bioequivalence between:

  • Dapagliflozin 10 mg tablets from Jiangsu Hansoh Pharmaceutical Group Co., Ltd.,China; and
  • Farxiga® 10 mg tablets from AstraZeneca Pharmaceuticals LP, USA; after a single-dose in healthy subjects under fasting conditions. The secondary objective of this study is to evaluate the safety and tolerability of the study treatments.
02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, non-smoking, male and female subjects, 18 years of age or older.
  2. ≥19 and ≤30 kg/m2.
  3. Females may be of childbearing or non-:

    • Childbearing potential:

      o Physically capable of becoming pregnant

    • Non-childbearing potential:

      • Surgically sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation); and/or
      • (no menstrual period for at least 12 consecutive months without any other medical cause).
  4. Willing to use acceptable, effective methods of .
  5. Able to tolerate venipuncture.
  6. Be informed of the nature of the study and give written consent prior to any study procedure.

Exclusion criteria

Exclusion Criteria:

  1. Known history or presence of neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  2. Known or suspected carcinoma.
  3. Known history or presence of or idiosyncratic reaction to dapagliflozin or any other drug substances with similar activity.
  4. Known history or presence of congestive heart failure, volume depletion, hypotension, and/or electrolyte imbalances.
  5. Known history or presence of pancreatitis, DM, lactic acidosis, or acute or chronic metabolic acidosis, including diabetic ketoacidosis.
  6. Known history or presence of clinically significant angioedema.
  7. Known history or presence of clinically significant lactose, galactose, or fructose intolerance.
  8. Presence of hepatic or renal dysfunction.
  9. History of malabsorption within the last year or presence of clinically significant gastrointestinal disease.
  10. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
  11. Known history or presence of genital mycotic infections.
  12. History or presence of Fournier's gangrene (necrotising fasciitis of the perineum).
  13. History of drug or alcohol addiction requiring treatment.
  14. Presence of urinary tract infection, urosepsis, or pyelonephritis.
  15. Positive test result for , surface antigen, or antibody.
  16. Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants) or urine cotinine.
  17. Difficulty fasting or consuming standard meals.
  18. Use of tobacco or nicotine-containing products within 6 months prior to drug administration.
  19. Females who:

    • Have discontinued or changed the use of implanted, intrauterine, intravaginal, or injected hormonal within 6 months prior to drug administration;
    • Have discontinued or changed the use of oral or patch hormonal contraceptives within 1 month prior to drug administration;
    • Are pregnant (serum hCG consistent with pregnancy); or
    • Are lactating.
  20. Donation or loss of whole blood (including clinical trials):

    • ≥50 mL and \<500 mL within 30 days prior to drug administration;
    • ≥500 mL within 56 days prior to drug administration.
  21. Participation in a clinical trial that involved administration of an medicinal product within 30 days prior to drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results.
  22. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).
  23. Have had a tattoo or body piercing within 30 days prior to drug administration.
  24. Have clinically significant findings in vital signs measurements.
  25. Have clinically significant findings in a 12-lead .
  26. Have clinically significant abnormal laboratory values.
  27. Have significant diseases.
  28. Have clinically significant findings from a physical examination.
  29. Use of any of the following within 30 days prior to drug administration:

    • Drugs that alter gastrointestinal pH/movement (e.g., omeprazole, ranitidine);
    • Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism;
    • Diuretics (e.g., thiazide and loop diuretics);
    • Insulin and insulin secretagogues (e.g., sulphonyl ureas);
    • Mefenamic acid;
    • Pioglitazone;
    • Rifampin;
    • Simvastatin; or
    • Valsartan.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Test Product

    Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Drug: Dapagliflozin 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.

    Drug: Dapagliflozin 10 mg tablets

  • Active comparator
    Reference Product

    Manufactured by AstraZeneca Pharmaceuticals LP Drug: Farxiga® 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.

    Drug: Farxiga® 10 mg tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Peak plasma concentration (Cmax) of Dapagliflozin in plasma after administration of the test and the reference products. In Period 1 and Period 2, blood samples were collected at prior to dosing (0-hour) and 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 hours after drug administration.

    Time frame: up to Day 10 post-administration

  2. AUCt

    The area under the plasma concentration-time curve from zero to last measurable concentration (AUCt) of Dapagliflozin in plasma after administration of the test and the reference products. In Period 1 and Period 2, blood samples were collected at prior to dosing (0-hour) and 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 hours after drug administration.

    Time frame: up to Day 10 post-administration

  3. AUCinf

    The area under the plasma concentration-time curve from zero to infinity (AUCinf) of Dapagliflozin in plasma after administration of the test and the reference products. In Period 1 and Period 2, blood samples were collected at prior to dosing (0-hour) and 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 hours after drug administration.

    Time frame: up to Day 10 post-administration

Secondary outcomes

  1. Adverse Events

    AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with the treatment. All AEs are classified according to version 23.1 of MedDRA and reported with respect to incidence, frequency, severity, duration, relationship to the investigational medicinal product, action taken, and outcome.

    Time frame: up to Day 10 post-administration.

07

Study locations

1 site
  • Pharma Medica Research Inc.
    Toronto, Ontario, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Dec 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2021
First posted
May 11, 2021
StartActual
Dec 14, 2020
Primary completionActual
Dec 24, 2020
CompletionActual
Feb 4, 2021
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04880993
Responsible party
Sponsor
First posted
May 11, 2021
Start date
Dec 14, 2020
Primary completion
Dec 24, 2020
Completion
Feb 4, 2021
Last update
May 11, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion